By Rishika Sadam HYDERABAD, Oct 30 (Reuters) - Indian drug regulators ordered Sun Pharmaceutical Industries to stop ...

Prescription drops that promise fewer hours in reading glasses sound great, but is there a catch?

The Madison Metropolitan School District now has access to a mobile vision clinic, bringing eye screenings and free ...

The home secretary is expected to keep a 10-year wait for most migrants seeking permanent settlement, but exempt social care ...

Explores how gender governs eye care access in India, from childhood to old age, revealing systemic barriers and social norms ...

Global eye care nonprofit Orbis International is committing an estimated US$32 million in financial and technical ...

The action prevents Sun Pharma, India's biggest pharmaceutical company, from resuming ophthalmic drug production at the ...

And it’s a little spooky too.

The licaminlimab trial enrolled 176 patients, two-thirds with a TNFR1 variant tied to stronger response. Data expected late 2026.

The Canadian Ophthalmological Society (COS), the Eye Physicians and Surgeons Association of Alberta (EPSAA), and the Section ...

Indian regulators halted Sun Pharma's ophthalmic production at its Assam facility due to significant quality management ...